#USA #New York #Levi & Korsinsky #Securities Class Action #Unicycive Therapeutics

Unicycive Therapeutics Investor Alert: A Closer Look at the Securities Class Action

Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is currently under scrutiny as investors react to a recent class action lawsuit filed by Levi & Korsinsky, LLP. The complaint centers on allegations that the company misled investors regarding its third-party manufacturer's compliance with FDA regulations. This serious allegation arises following a significant drop in share value when the company revealed it had received a second Complete Response Letter (CRL) from the FDA.

Background of the Case

On June 30, 2026, Unicycive disclosed that the FDA had issued a second CRL for the resubmission of its new drug application for oxylanthanum carbonate. This announcement highlighted that the deficiencies identified by the FDA were the same issues discovered in a previous CRL issued in June 2025. Furthermore, the company admitted that the FDA had not performed an inspection of the vendor's manufacturing facility during the resubmission review process, raising questions about the reliability of statements made to investors over the preceding months.

The drastic market reaction was evident as Unicycive's shares fell an alarming 39.1%, or $3.01 per share, closing at $4.69 on unusually high trading volume following the announcement. Prior to the disclosure, shares had been priced at $7.70 just the day before, with a high of $8.56 observed on May 14, 2026. This swing in stock price has motivated a legal response from affected shareholders.

What the Lawsuit Entails

The class action lawsuit contends that Unicycive Therapeutics had continuously assured investors about the progress of its vendor’s compliance with good manufacturing practices (cGMP), despite a lack of direct inspection or verification. This raises critical concerns as it suggests that the company's assurances were baseless, misinforming investors regarding the state of the regulatory approval process.

The lawsuit covers shareholders who purchased securities during the specified class period from December 29, 2025, to June 29, 2026. Those investors, who believe they suffered losses due to these misleading statements, may still be eligible to recover damages, especially if they can provide brokerage records that demonstrate their transactions.

Key Details of the Class Action:

• - Class Period: December 29, 2025 – June 29, 2026
• - Stock Decline: 39.1% drop post-announcement
• - Closing Price After Announcement: $4.69 per share
• - Eligibility Deadline for Lead Plaintiff: November 2, 2026

The Importance of the Market Reaction

Joseph E. Levi, the attorney representing the class of investors, has emphasized the significance of the market reaction. A nearly 40% drop in stock price within a single trading session reflects a profound correction of previously inflated valuations that were not anchored in accurate information. The allegations, if proven true, underscore the need for corporate transparency, particularly regarding critical factors that can materially affect stock prices and investor confidence.

Steps for Current Investors

Unicycive investors should take immediate action by gathering relevant records to substantiate their claims. This includes documenting purchase dates, quantities of shares purchased, and prices paid to establish evidence of their losses. Interested investors can reach out to Levi & Korsinsky for a no-cost assessment of their potential eligibility to recover losses. Importantly, the lawsuit accommodates those who may have already sold their shares at a loss, thus allowing a broader range of affected investors to participate in potential recovery efforts.

Conclusion

As the legal proceedings unfold, it will be essential for both the involved parties and investors to remain informed. The outcome could have substantial implications for Unicycive Therapeutics and its shareholders, not to mention the broader landscape for compliance disclosure in the pharmaceutical industry. Investors who feel aggrieved by their experiences with Unicycive are urged to consider their options carefully and consult with legal professionals at Levi & Korsinsky.